Thomas Borcholte

DETEK AG is a German economic investigation company founded in 1978. The private company is based in Hannover, Germany. The company provides services in various scenarios where economic investigators are needed. The text in the company's description is in both German and English, indicating that they may operate in both countries or provide services to clients who speak either language.

Part of Nuclea Biotechnologies, Inc., Wilex, Inc. develops medical diagnostic tests. The company is based in Cambridge, MA. The CEOs of the company are Thomas Borcholte, Olaf G. Wilhelm. Wilex was acquired by Nuclea Biotechnologies, Inc. from Heidelberg Pharma AG on September 06, 2013.

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK.

NextGen Sciences Ltd. provides technologies and reagents for molecular biology and protein research. Its advanced products automate and simplify complex research techniques, saving time and resources, improving results, and accelerating discovery. The company was founded on January 28, 2000 by Kevin Auton and David Wigley and is headquartered in Huntingdon, the United Kingdom.

NextGen Group Plc provides protein biomarker testing services for pharmaceutical and biotech companies. Its services include biomarker discover, assay development and testing laboratory. The company's biomarker assay used to test pre-clinical and clinical samples for drug efficacy and safety, and for the development of personalized treatment for patients. Its biomarker services include protein identification, characterization, quantitation and proteome mapping. The company was founded on September 7, 2005 and is headquartered in London, the United Kingdom.

TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.